tradingkey.logo

Rockwell Medical prelim Q4 revenue rises

ReutersJan 20, 2026 11:08 AM


Overview

  • Healthcare company's preliminary Q4 revenue rises, cash flow positive for second time in 2025

  • Company expects Q4 gross margin to rise to 22%, up from 14% in Q3


Outlook

  • Company focuses on revenue growth, profitability, and portfolio diversification for 2026


Result Drivers

  • REVENUE INCREASE - Rockwell Medical reported a considerable increase in preliminary Q4 revenue, exceeding analyst expectations

  • GROSS MARGIN IMPROVEMENT - preliminary Q4 gross margin rose to 22%, up from 14% in Q3, due to improved operational efficiencies and reduced expenses

  • CASH FLOW POSITIVE - Company achieved positive cash flow from operations in Q4, marking the second positive quarter in 2025


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Sales

Beat

$18.60 mln

$16.55 mln (2 Analysts)


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Rockwell Medical Inc is $3.75, about 291.7% above its January 16 closing price of $0.96

Press Release: ID:nBw205KS8a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI